GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹109 Cr | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹109 Cr |
| Mar2024 | ₹-357 Cr |
| Mar2023 | ₹2,621 Cr |
| Mar2022 | ₹1,270 Cr |
| Mar2021 | ₹2,804 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹109 Cr | Positive | |
| Mar2024 | ₹-357 Cr | Negative | |
| Mar2023 | ₹2,621 Cr | 106.48 | |
| Mar2022 | ₹1,270 Cr | -54.72 | |
| Mar2021 | ₹2,804 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹57,520.8 Cr | 1.1% | 2.4% | 39.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹412,062.0 Cr | 0.4% | 2.6% | NA | Stock Analytics | |
| DIVIS LABORATORIES | ₹164,192.0 Cr | -4.5% | 0.7% | 3.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹144,129.0 Cr | 5% | 4.1% | 37.2% | Stock Analytics | |
| CIPLA | ₹108,513.0 Cr | -0.5% | -3.4% | -6.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,250.0 Cr | 1.2% | 10.2% | 4.8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.1% |
2.4% |
39.9% |
| SENSEX | -1% |
-0.1% |
7.9% |
You may also like the below Video Courses